Extracellular Vesicle Drug Delivery via Covalent Anchoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems, such as antibody-drug conjugates, face limitations in payload capacity and specificity, leading to reduced potency and increased systemic toxicity, while extracellular vesicles like exosomes have shown limited clinical efficacy in therapeutic applications.
Innovation Solution
Development of extracellular vesicles with biologically active molecules covalently linked via anchoring moieties, such as sterols, lipids, or vitamins, to enhance targeting specificity and payload capacity, potentially improving therapeutic delivery and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If biologically active molecules are conjugated to antibodies to limit exposure of non-target tissues, then targeting specificity is improved, but payload capacity is limited (typically 2-6 molecules per antibody)
Solution Approach 1:
The patent uses extracellular vesicles as a universal delivery platform that can accommodate multiple different biologically active molecules simultaneously, replacing the antibody platform's limitation of carrying only 2-6 molecules. The vesicle surface can be engineered to display numerous targeting ligands while the interior can encapsulate large quantities of therapeutic payloads, achieving both high specificity and high payload capacity through multi-functional design
Solution Approach 2:
The patent employs a nested structure where biologically active molecules are encapsulated within the extracellular vesicle interior, while targeting ligands are displayed on the external surface. This nested arrangement allows the therapeutic molecules to be protected and concentrated inside the vesicle while the surface displays multiple copies of targeting moieties, thereby achieving both high payload capacity and high targeting specificity simultaneously
2Quantity of substance
If more molecules are attached to increase payload capacity, then potency is improved, but availability of specific antibodies decreases
Solution Approach 1:
The patent replaces the antibody-specific approach with a universal extracellular vesicle platform that can be engineered to display any desired targeting ligand on its surface. This universality allows the system to accommodate various antibody types, peptide ligands, or other targeting molecules without being constrained by antibody availability or the 2-6 molecule attachment limit, enabling flexible adaptation to different therapeutic targets
Solution Approach 2:
The extracellular vesicle acts as an intermediary carrier that decouples the relationship between targeting ligands and therapeutic payloads. Instead of directly conjugating molecules to antibodies, the vesicle surface serves as an intermediate platform that can display multiple copies of targeting ligands while encapsulating numerous therapeutic molecules in its interior, thereby overcoming the limitations of direct antibody conjugation
3Ease of manufacture
If extracellular vesicles are used as drug delivery vehicles, then advantages over traditional methods are achieved, but clinical efficacy remains limited
Solution Approach 1:
The patent applies preliminary engineering modifications to extracellular vesicles before clinical use, including surface engineering to display specific targeting ligands and optimization of payload encapsulation. By pre-engineering the vesicles with specific functional properties (targeting moieties, payload capacity, stability features) before administration, the system overcomes the limited clinical efficacy of native or minimally modified vesicles used in earlier trials
Solution Approach 2:
The patent systematically modifies key parameters of extracellular vesicles to enhance clinical efficacy, including changing surface properties by displaying specific ligands, optimizing payload concentration and type, adjusting vesicle size and stability characteristics. These parameter changes transform the vesicles from basic delivery vehicles with limited efficacy into engineered platforms with optimized therapeutic performance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables more effective targeting of specific tissues while minimizing systemic exposure, potentially overcoming the limitations of existing drug delivery methods by increasing the payload capacity and specificity of therapeutic agents.
Implementation Method 1
comprising a biologically active molecule covalently linked to the EV via an anchoring moiety
Data Source
AI summary
The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via an anchoring moiety, which may be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.